Pamrevlumab

DelveInsight's 'Duchenne Muscular Dystrophy (DMD) Pipeline Insight, 2024' analyzes over 75 pipeline drugs from 75+ companies, focusing on recent FDA, EMA, and PMDA approvals, clinical trials, emerging therapies, and key players like Roche, Santhera, and Sarepta. The report covers various stages of development, routes of administration, and mechanisms of action, offering insights into the evolving DMD therapeutics landscape.

Luca Richeldi discussed IPF clinical trial failures at ERS Congress 2024, highlighting the need to learn from past setbacks to improve future trial designs. He noted that not all negative trials are failures and cited the 2012 study as an example. Richeldi analyzed recent phase 3 trials (ziritaxestat, zinpentraxin alfa, pamrevlumab) that faced challenges, emphasizing the importance of larger sample sizes, longer study durations, and handling outliers. He proposed adaptive trial designs, rigorous statistical methods, and focusing on patient-relevant outcomes to enhance future IPF research.